Asia Pacific Expected To Account For Half Of Global Probiotics Sales This Year

Interest in probiotics in APAC is expected to continue to grow driven in part by the “K-food” (Korean food) wave, Euromonitor International reports.

Asia Pacific region is a major consumer of probiotics • Source: Shutterstock

Asia Pacific is expected account for nearly half (44%) of the global volume of probiotic cultures sold as food ingredients in 2024, according to Euromonitor International.

“Asia Pacific represents a bright spot for innovation opportunities in probiotics, given its maturity in packaged food applications compared to the rest of the world,” commented

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Wellness

OTC Marketing Awards 2025 Open For Entries

 
• By 

Find out how to enter the OTC Marketing Awards before the 1 September entry deadline.

US FDA Supplement Office Chief Eyes ‘Movement’ This Year On NDI Notifications Final Guidance

 

“We've made some progress and really hope to see some movement as we move forward this year,” says FDA Office of Dietary Supplement Programs director Cara Welch.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By 

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By 

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

More from Ingredients & Safety

German Industry Urges ECHA To Reconsider ‘De Facto’ EU Ethanol Ban

 
• By 

Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.

AESGP: ‘No Evidence’ Of Antimicrobial Resistance With OTC Antifungals Or Antivirals

 
• By 

Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By 

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.